US7311925B2 - Methods and compositions for blocking microbial adherence to eukaryotic cells - Google Patents
Methods and compositions for blocking microbial adherence to eukaryotic cells Download PDFInfo
- Publication number
- US7311925B2 US7311925B2 US10/053,299 US5329902A US7311925B2 US 7311925 B2 US7311925 B2 US 7311925B2 US 5329902 A US5329902 A US 5329902A US 7311925 B2 US7311925 B2 US 7311925B2
- Authority
- US
- United States
- Prior art keywords
- isoleucine
- composition
- microbial
- bacteria
- blocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000000813 microbial effect Effects 0.000 title claims abstract description 20
- 210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 15
- 230000000903 blocking effect Effects 0.000 title claims abstract description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 131
- 229960000310 isoleucine Drugs 0.000 claims abstract description 118
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 116
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 230000000845 anti-microbial effect Effects 0.000 claims description 7
- 235000021323 fish oil Nutrition 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- -1 echimacea Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 235000004426 flaxseed Nutrition 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 3
- HVWGTGTZCBPIOH-UHFFFAOYSA-N 1lambda2-stannole Chemical class [Sn]1C=CC=C1 HVWGTGTZCBPIOH-UHFFFAOYSA-N 0.000 claims description 3
- 240000002234 Allium sativum Species 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 239000004212 Cryptoxanthin Substances 0.000 claims description 3
- AGPKZVBTJJNPAG-CRCLSJGQSA-N D-allo-isoleucine Chemical compound CC[C@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-CRCLSJGQSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 235000009134 Myrica cerifera Nutrition 0.000 claims description 3
- 244000233952 Polygonum bistorta Species 0.000 claims description 3
- 235000014258 Polygonum bistorta Nutrition 0.000 claims description 3
- 240000003085 Quassia amara Species 0.000 claims description 3
- 235000009694 Quassia amara Nutrition 0.000 claims description 3
- 244000061457 Solanum nigrum Species 0.000 claims description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims description 3
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 3
- 235000004611 garlic Nutrition 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 235000020737 peppermint extract Nutrition 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 229940013788 quassia Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims description 3
- 239000001775 zeaxanthin Substances 0.000 claims description 3
- 229940043269 zeaxanthin Drugs 0.000 claims description 3
- 239000006000 Garlic extract Substances 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 235000020706 garlic extract Nutrition 0.000 claims description 2
- 235000012680 lutein Nutrition 0.000 claims description 2
- 229960005375 lutein Drugs 0.000 claims description 2
- 239000001656 lutein Substances 0.000 claims description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 235000014705 isoleucine Nutrition 0.000 description 111
- 241000186660 Lactobacillus Species 0.000 description 14
- 230000036541 health Effects 0.000 description 14
- 208000002551 irritable bowel syndrome Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000006041 probiotic Substances 0.000 description 13
- 230000000529 probiotic effect Effects 0.000 description 13
- 235000018291 probiotics Nutrition 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 239000002855 microbicide agent Substances 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000002345 respiratory system Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Chemical class 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 208000037009 Vaginitis bacterial Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 244000298479 Cichorium intybus Species 0.000 description 4
- 235000007542 Cichorium intybus Nutrition 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 206010012742 Diarrhoea infectious Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000741 diarrhetic effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000310 rehydration solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241001473768 Ulmus rubra Species 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 229940059082 douche Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 238000011418 maintenance treatment Methods 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- 229960003908 pseudoephedrine Drugs 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- KWAIBDZWGOZFDA-FHAQVOQBSA-N (2s,3s)-2-amino-3-methylpentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O KWAIBDZWGOZFDA-FHAQVOQBSA-N 0.000 description 1
- GMKATDLSKRGLMZ-WHFBIAKZSA-N (2s,3s)-2-amino-n-hydroxy-3-methylpentanamide Chemical compound CC[C@H](C)[C@H](N)C(=O)NO GMKATDLSKRGLMZ-WHFBIAKZSA-N 0.000 description 1
- JVQYSWDUAOAHFM-BYPYZUCNSA-M (S)-3-methyl-2-oxovalerate Chemical compound CC[C@H](C)C(=O)C([O-])=O JVQYSWDUAOAHFM-BYPYZUCNSA-M 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000037838 Chronic pouchitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010052806 Drug tolerance increased Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001304248 Progne modesta Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 208000033847 bacterial urinary tract infection Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 150000002519 isoleucine derivatives Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000014075 nitrogen utilization Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 244000000072 vaginal pathogen Species 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/126—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
Definitions
- This invention relates to methods and compositions for preventing the adhesion of microorganisms to epithelial or other eukaryotic cell surfaces.
- Infection by microbial organisms involves initial adherence to a surface. Failure of adherence is believed to prevent subsequent invasion of otherwise intact epithelial surfaces. Hence methods have been developed/conceived to block infection through blockade of adherence. In general these approaches have focused on the development of substances which bind to either cellular receptors onto which bacteria dock, or substances which complex with microbial determinants, such as antibodies.
- This invention relates to methods for blocking the adherence of microorganisms to epithelial cells and other eukaryotic cells by applying isoleucine to the surface of the cells, i.e. this invention relates to a method for preventing or treating microbial infections by the application or administration of a composition containing isoleucine.
- the invention also relates to compositions containing at least one isoleucine compound for applying to the above cell surfaces.
- the method of the present invention is carried out by applying to a eukaryotic cell surface in a mammal a pharmacologically acceptable composition comprising at least one compound selected from the group consisting of isoleucine, an active isomer thereof, and an active analog thereof, to a eukaryotic cell surface in a microbial blocking quantity.
- the microbial blocking quantity will vary depending on the isoleucine compound selected. In general, however, a quantity of from 0.1 ug/cm 2 to 1 gm/cm 2 of eukaryotic cell surface is effective, preferably from 3 ug/cm 2 to 100 ug/cm 2 , and more preferably from 10 ug/cm 2 to 100 ug/cm 2 .
- Isoleucine stereoisomers that can be used in the present invention include L(+)-isoleucine, which is the naturally occurring form, DL-isoleucine, which is a racemic mixture and is the synthetic form, D( ⁇ )-allo-isoleucine, and L(+)-allo-isoleucine, although the latter two compounds are much less active.
- Active analogs of isoleucine include alpha-keto-methyl valerate, isoleucine hydroxamate, and isoleucine butyrate.
- L(+)-isoleucine in the typical mammalian diet is not sufficient to provide an effective microbial blocking quantity to eukaryotic cells.
- the method of the invention will reduce microbial adherence on all eukaryotic cell surfaces exposed to microbes. These include the oral cavity, pharynx, respiratory tract, conjunctivae, gastrointestinal tract, skin, and the genitourinary tract, including the vagina, cervix, urethra and bladder.
- the present method can be used to prevent or treat infections or medical conditions caused by microbes whose attachment or growth on the surface of eukaryotic cells, including epithelial cells, can be comprised by an isoleucine induced state of “resistance” on the surface of the target cell.
- Isoleucine is an essential amino acid, meaning that while it is critical for normal health and nutrition it cannot be synthesized within the body but must be obtained from an external source, usually via food intake. It is well established that a state of general malnutrition may lead to immune dysfunction and increased probability of infection. Specific withholding or nutritive limitation of any essential amino acid, including isoleucine, might likewise be expected to harm health or affect immune function. Such limitations do in fact affect certain immune parameters and resistance to certain experimental infections in mice (Petro T. M and Bhattacharjee J. K. Effect of dietary amino acid limitations upon native levels of murine immunoglobulins, transferrin, and complement. Infect. Immun. 27, 513-518,1980; and Petro T. M and Bhattacharjee J. K. Effect of dietary amino acid limitations upon the susceptibility to Salmonella typhimurium and the effect upon humoral and cellular immune responses in mice. Infect. Immun. 32, 251-259, 1981).
- the approach taken in the implementation of the current invention does not relate to these general and specific states of starvation but rather confers health benefits upon hosts or patients in states of full nutrition as well as poor nutrition.
- the use of isoleucine as an adhesion inhibitor for the prevention and treatment of disease is further distinguished from its role as an essential nutrient in that may confer benefit after application to the surface of an epithelial layer (such as on the gums, in the vagina, in the nasal mucosa, on the skin, in the eyes, on wounds, in the GI tract, and the like), with no need for systemic digestive absorption, transport, processing, and utilization.
- treatment with isoleucine will not affect the adhesion of all types or species of microbes equally, and because in humans and animals the microbes living on and near epithelial surfaces are in competition with one another for adhesion space and sites, treatment with isoleucine is expected to alter the numbers and relative abundance of various microbes that constitute the microbial flora of the epithelial surface and the anatomical compartment it surrounds.
- Such an effect of various other adhesion inhibitors has been observed and reported. See e.g. Kelly C G and Younson J S. Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces. Expert Opin. Investig. Drugs 9, 1711-1721, 2000.
- isoleucine in addition to preventing or treating infection or other medical conditions by a direct effect of isoleucine on the adhesion of detrimental microbes to epithelial and other eukaryotic cells, isoleucine may have further beneficial effects by a resultant alteration of the populations of resident microflora.
- the benefits of promoting particular microflora are well documented and include the prevention and treatment of infectious diarrhea. See e.g. Arvola T., et al, Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infection: a randomized study, Pediatrics 104, 664, 1999; Vanderhoof J A, et al, Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children.
- the method of the invention will either prevent adhesion of microbes to eukaryotic cells or will at least reduce their abundance.
- the present method will work in man and other mammals, including companion animals and agricultural animals.
- the invention also comprises a method of determining an effective dose of isoleucine comprising measuring the numbers and types of microbes contained in an epithelially lined compartment or contained in a sample taken from such a compartment, and adjusting the quantity of isoleucine accordingly.
- the methods of treatment described above pertain to, but are not limited to, the oral cavity and its surfaces, the entire respiratory tract and its surfaces, the entire gastrointestinal tract and its surfaces, the entire urogenitary tract and its surfaces, and the skin.
- the invention also relates to pharmacologically acceptable compositions comprising:
- component A) is preferably present in from 0.002 to 50% by weight, and more preferably from 0.1 to 25% by weight.
- Component B) substances will depend on the nature of the composition.
- component B) when the composition is a dental care product, component B) can be one or more of a fluoride, xylitol, an antibody, and an anti-microbial agent.
- anti-microbial agent is understood to include microbicides.
- component B) when the composition is a nasal spray, component B) can be one or more of zinc ions, a decongestant, and an anesthetic.
- component B) can be one or more of an antimicrobial substance or an anesthetic.
- component B) can be one or more of an antioxidant, a vitamin, probiotic bacteria, live bifidobacteria, live streptococci, live enterococci, heat-killed probiotic bacteria, peppermint oil or extract, menthol, quassia, bistort, ginger, angelica, bayberry, chamomile, fish oil, a fatty acid, an omega-3 fatty acid, fiber, flaxseed, slippery elm, niacin, a plant extract, garlic or garlic extract, calcium, stannol esters, lutein, zeaxanthin, cryptoxanthin, isoflavone, an anti-inflammatory compound, aspirin, ibuprofen, and acetaminophen.
- an antioxidant a vitamin, probiotic bacteria, live bifidobacteria, live streptococci, live enterococci, heat-killed probiotic bacteria, peppermint oil or extract, menthol, quassia, bistort, ginger,
- component B) can be one or more of an antifungal agent, an antibacterial agent, live probiotic microorganisms, and live lactobacilli.
- component B) can be one or more of chicory, fiber, live probiotic bacteria, silage, grain, corn, soybeans, and wheat.
- the invention also includes a composition comprising a rehydration solution containing glucose or other sugars and/or salts and isoleucine.
- the invention further includes a composition comprising an infant formula or food containing milk products and/or soy products and isoleucine.
- the invention also relates to gauze and other wound dressings containing or coated with isoleucine.
- the invention further relates to dental floss, ribbon, or tape coated with or impregnated with isoleucine.
- the invention also includes a composition comprising isoleucine and/or an active isomer thereof and methylcellulose or carageenan.
- various other end use products can include isoleucine as the only pharmacologically active component.
- Optional component C) can be one or more of a carrier material such as water, ethanol, oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like, an excipient such as methylcellulose, carageenan, and the like.
- a carrier material such as water, ethanol, oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like, an excipient such as methylcellulose, carageenan, and the like.
- the invention encompasses various compositions containing isoleucine that are useful in the application of the subject methods. More specifically, the composition may be used to prevent the adherence of microbes to the surface of epithelial and other eukaryotic cells and to prevent or treat various disease states or conditions.
- the invention encompasses a method of treating or preventing diseases of the oral cavity by the administration of isoleucine containing compositions.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the oral cavity to prevent or treat, for example, gingivitis.
- the isoleucine containing composition may be applied as a dry powder, a paste, a gel, as a solution, in a chewing gum, in a lozenge, or via a device such as a dental floss or ribbon.
- the invention also relates to methods or compositions containing isoleucine useful in changing the numbers or relative numbers of microbes that reside in or on the surface of the oral cavity or gums.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in oral health but work by mechanisms distinct from that of isoleucine. Combining isoleucine with these substances is expected to result in a composition with greater activity than isoleucine or the individual ingredient when used as single agents due to additive or synergistic effects of the combined ingredients.
- the invention specifically encompasses compositions containing isoleucine and fluoride, xylitol, an antibody, an anti-microbial substance, mint flavoring or extract, or a microbicidal substance.
- the invention also relates to a method of preventing or treating various conditions or disease states of the urogenital tract.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the urogenital tract to prevent or treat, for example, bacterial vaginosis, urinary tract infection, or vaginal yeast infection.
- the isoleucine containing composition may be applied as a dry powder, a paste, as a solution, or in a gel.
- a gel may be comprised of isoleucine in methylcellulose.
- the composition may also be used as a female douche.
- the invention also relates to methods or compositions containing isoleucine useful in changing the numbers or relative numbers of microbes that reside in or on the surface of the urogenital tract.
- Applications of isoleucine containing compositions may be used, for example, to increase the numbers or relative portion of lactobacillus species in the vagina to confer the known health benefits of increasing lactobacilli in that compartment.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting urogenital health but work by mechanisms distinct from that of isoleucine.
- the invention includes a method or a composition relating to a method of preventing or treating various conditions or disease states of the gastrointestinal tract.
- the invention also relates to methods or compositions used to apply isoleucine to the epithelial surfaces of the gastrointestinal tract to prevent or treat, for example, diarrhea, constipation, irritable bowel syndrome, or inflammatory bowel disease.
- the isoleucine containing composition may be ingested as a dry powder, a paste, as a solution, in a gel, as a tablet, lozenge, capsule, or bolus.
- the isoleucine containing composition may also be a food product such as yogurt, pudding, baked product, drink, soup, gum, candy, dairy product, infant formula, baby food, or rehydration solution.
- the invention specifically encompasses pre-measured dosage containers of an isoleucine containing composition such as a paper packet.
- the invention also relates to use of isoleucine in changing the numbers or relative numbers of microbes that reside in or on the surface of the gastrointestinal tract.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting gastrointestinal health but work by mechanisms distinct from that of isoleucine.
- the invention also relates to a method of preventing or treating various conditions or disease states of the cardiovascular system by altering levels of cholesterol and certain other blood lipids. This beneficial alteration of lipid levels is a result of change in the numbers or relative numbers of gastrointestinal microbes that affect lipid metabolism.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the gastrointestinal tract to prevent or treat cardiovascular disease or increased blood lipid levels.
- the isoleucine containing composition may be ingested as a dry powder, a paste, as a solution, in a gel, as a tablet, capsule, or bolus.
- the isoleucine containing composition may also be a food product such as yogurt, pudding, spread, baked product, drink, soup, gum, candy, or dairy product.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting cardiovascular health and/or the alteration of blood lipid levels but work by mechanisms distinct from that of isoleucine.
- live probiotic bacteria such as lactobacilli or bifidobacteria
- non-digestible carbohydrates fructo-oligosaccharides
- pre-biotic materials pre-biotic materials
- fish oil omega-3 fatty acids
- the invention also relates to a method of preventing or treating various conditions or disease states of the skin.
- the invention includes a method or a composition or device used to apply isoleucine to the epithelial surfaces of the skin to prevent or treat, for example, acne or fungal infection.
- the invention further includes a method or a composition or device used to apply isoleucine to treat a wound, prevent or treat wound infection, or to promote wound healing or closure.
- the invention specifically encompasses a skin cream, ointment, gel, or solution containing isoleucine.
- the invention specifically encompasses a wound cream, ointment, gel, or solution containing isoleucine.
- the invention also includes a device such as a wound covering comprising cloth or gauze containing or impregnated with isoleucine.
- the invention also includes the use of isoleucine in changing the numbers or relative numbers of microbes that reside in or on the surface of the skin.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting skin or wound health.
- the invention specifically encompasses compositions containing isoleucine and one or more of a microbicidal substance, an anesthetic, and a cleaning agent.
- the invention also relates to a method of preventing or treating various conditions or disease states of the respiratory tract.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the respiratory tract to prevent or treat, for example, the common cold, sinusitis, or lung infection.
- the isoleucine containing composition may be applied as a dry powder or particle, a paste, as a solution, as a spray, in a gum, in a lozenge, in a candy, or in a gel.
- the invention also relates to the use of isoleucine in changing the numbers or relative numbers of microbes that reside in or on the surface of the respiratory tract.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting respiratory health but work by mechanisms distinct from that of isoleucine.
- the invention specifically encompasses compositions containing isoleucine and one or more of a microbicidal substance, an anti-microbial substance, a decongestant, xylitol, diphenhydramine, pseudoephedrine, dextromethorphan, echinacea, and zinc ions.
- the invention also relates to a method of preventing or treating various conditions or disease states of the ear.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the oral cavity, respiratory tract, or inner ear to prevent or treat, for example, otitis media.
- the isoleucine containing composition may be applied as a dry powder or particle, a paste, as a solution, as a spray, in a gum, in a lozenge, in a candy, in a syrup, or in a gel.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting health of the ear and its associated structures but work by mechanisms distinct from that of isoleucine.
- compositions containing isoleucine and one or more of a microbicidal substance, an antimicrobial substance, a decongestant, diphenhydramine, pseudoephedrine, xylitol, and zinc ions specifically encompasses compositions containing isoleucine and one or more of a microbicidal substance, an antimicrobial substance, a decongestant, diphenhydramine, pseudoephedrine, xylitol, and zinc ions.
- the invention also relates to a method of preventing or treating various conditions or disease states of companion animals.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the gastrointestinal tract, respiratory tract, oral cavity, gums, skin, or urogenital tract to prevent or treat, for example, diarrhea, constipation, halitosis, or gum disease.
- the isoleucine containing composition may be applied by any of the means described above including specifically as a toothpaste or food item.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting the health of companion animals but work by mechanisms distinct from that of isoleucine.
- the invention specifically encompasses compositions containing isoleucine and one or more of a microbicidal substance, non-digestible carbohydrates, fructo-oligosaccharides, chicory, live probiotic bacteria, and fiber.
- the invention also relates to a method of preventing or treating various conditions or disease states and of promoting health and weight gain of agricultural or aqua-cultured animals.
- the invention includes a method or a composition used to apply isoleucine to the epithelial surfaces of the gastrointestinal tract, respiratory tract, oral cavity, gums, skin, or urogenital tract to prevent or treat, for example, diarrhea, respiratory infection, or the carriage of pathogenic organisms.
- the isoleucine containing composition may be applied by any of the means described above including specifically as spray or incorporated into the animals feed.
- the present invention also encompasses compositions containing isoleucine and other substances that have utility in promoting the health of agricultural or aqua-cultured animals but work by mechanisms distinct from that of isoleucine.
- the invention specifically encompasses compositions containing isoleucine and one or more of a microbicidal substance, chicory, silage, non-digestible carbohydrates, fructo-oligosaccharides, live probiotic bacteria, and grain
- isoleucine was applied as a pure crystalline powder directly to the gums.
- the individuals were normal human volunteers. Each individual had clinically evident low grade gingivitis, as determined by the puffiness of the gingival margin and a history of some bleeding during normal dental brushing. Oral health care comprised twice daily flossing and dental brushing with a non-medicated toothpaste. No oral antiseptic was used. The individuals were not taking antibiotics.
- Isoleucine was applied by application of powder on the fingertip to the outer and inner gum margins of the upper and lower jaws. The entirety of the gingival surface was covered manually, twice daily. The AM application was performed following breakfast, immediately after brushing. The PM application was conducted prior to retiring for sleep.
- Gingival scrapings were taken in the morning prior to normal oral care and prior to eating. Prior to scraping, the subject rinsed the mouth with a cup of water to wash free particulate matter, unattached cells, and bacteria.
- Scrapings were taken 3 days and 1 day prior to isoleucine administration and 1, 3, 5, and 7 days during isoleucine application. Gingival scrapings taken prior to isoleucine use revealed epithelial cells covered with numerous micro-colonies. The bacteria adherent were represented by several different species, distinguished by morphology. Of 100 cells examined, greater than 90 exhibited adherent bacteria almost completely covering the surface of the epithelial cell. At least 200 bacteria were counted on the average on each cell.
- a gingival smear taken on Day ( ⁇ 1) revealed numerous polymorphonuclear cells, a sign of inflammation.
- epithelial cells recovered were densely laden with adherent bacteria. Breath prior to oral hygiene in the AM, as evaluated by the examiner, was described as “bad”. This odor is a byproduct of bacterial metabolism and resembles that of isobutyric acid.
- Gingival smears taken on Day 1 following initiation of isoleucine application revealed little change in the number of epithelial cells covered with a dense coat of bacteria. Smears on Day 3 revealed dramatic reduction in adherent bacteria. Of 100 cells examined, now only 40 were fully covered with bacteria. No neutrophils were evident. Most cells had fewer than 100 total adherent bacteria. Most bacteria observed were isolated single or double forms. Few “microcolonies” representing contiguous groupings of greater than 4 organisms could be counted on these cells.
- isoleucine was administered to treat infectious diarrhea.
- three individuals were naturally innoculated by a common agent.
- the nature of the diarrheal agent is not known.
- the duration of diarrhea was consistent with an infectious etiology.
- Isoleucine was utilized based on the hypothesis that reduction in microbial adherence would likely limit the continued re-infection of the gut wall by the agent, and/or prevent attachment of opportunistic commensal organisms.
- MZ, BZ, JZ Three members of a family traveling in the Middle East (MZ, BZ, JZ) contracted watery diarrhea, associated with food intolerance, following a meal they shared at a restaurant. Each individual had been in excellent health without prior history of GI complaints. All were unmedicated, including aspirin or antihistamines. Onset of gastrointestinal disturbance occurred in each individual within 5 hours and exhibited the same clinical characteristics. Diarrhea was watery, without gross blood, minimal mucous, slight fever with chills, no nausea, and persistence of hunger. Peristalsis was vigorous and increased by ingestion of food. Each individual was placed on a diet restricted to clear liquids (juices and soda), digestible carbohydrates (bread, rice, candy). No medications were administered.
- ILE oral isoleucine
- BZ and JZ both continued to experience diarrhea unabated until about 11 days after ingestion of the infectious agent, with stool frequency decreasing noticeably. No stools were passed on day 12 and recovery was associated with return of food tolerance.
- isoleucine therapy was associated with a shortening of the duration of diarrhea by approximately three days.
- IBS irritable bowel syndrome
- IBS insulin-derived suppository
- GI tract GI tract
- probiotic “good” bacteria Two women, each in their mid-50's, presented with a history of IBS of over 20 years, in each case.
- IBS was characterized by a sense of bloating experienced after eating cooked or raw vegetables, fruits, and meat. Each individual experienced urgency to move her bowels several times a day to an extent that often awakened the individuals from sleep. Bloating was accompanied by abdominal discomfort, described as mild cramps. Individuals felt “gassy” most of the day. Each individual was given isoleucine, 1 tsp, twice a day, each dose mixed in 1 ⁇ 2cup of yogurt. The yogurt was included to promote reinoculation of the GI tract with probiotic “good” bacteria.
- yogurt itself had little effect on the IBS experienced by these individuals.
- isoleucine administration Within 2 days of isoleucine administration, bloating, urgency to defecate, and gassiness had disappeared. Both individuals described the state of their bowel function as “normal”, for the first time in 20 years. Each individual was maintained on isoleucine for 1 month with consistent response. Each was then withdrawn from isoleucine, and provided yogurt unsupplemented with isoleucine. Within about 2 days both women recorded a reappearance of the former symptoms of IBS.
- isoleucine was administered locally to the vagina to treat the symptoms of bacterial vaginosis.
- microbial growth, inflammation, and associated signs of malodorous discharge and symptoms such as pruritis can be treated.
- Isoleucine was self-administered as a powder locally within the vaginal cavity digitally, twice a day. Within 2 days symptoms of vaginosis disappeared. Isoleucine therapy was continued for several days following termination of menstrual discharge, and then stopped. The individual remained symptom free following cessation of isoleucine administration. Isoleucine was again administered during the following months, cycled as described initially. Based on the symptoms and signs, the chronic vaginosis appears to have been effectively cured.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
-
- A) from 0.001 to 99% by weight of isoleucine;
- B) at least one additional pharmacologically active substance; and, optionally,
- C) at least one pharmacologically acceptable carrier material.
Microbial Adherence to Gingival Epithelial Cells vs. Isoleucine |
Treatment (% cells) |
Day | 0 Bacteria | 1-10 Bacteria | 10-100 Bacteria | Contiguous lawn |
−1 | 0 | 5 | 5 | 90 |
1 | 0 | 10 | 10 | 80 |
3 | 15 | 15 | 30 | 40 |
7 | 80 | 15 | 0 | 5 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/053,299 US7311925B2 (en) | 2001-01-22 | 2002-01-17 | Methods and compositions for blocking microbial adherence to eukaryotic cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26304901P | 2001-01-22 | 2001-01-22 | |
US10/053,299 US7311925B2 (en) | 2001-01-22 | 2002-01-17 | Methods and compositions for blocking microbial adherence to eukaryotic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020131996A1 US20020131996A1 (en) | 2002-09-19 |
US7311925B2 true US7311925B2 (en) | 2007-12-25 |
Family
ID=26731677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/053,299 Expired - Fee Related US7311925B2 (en) | 2001-01-22 | 2002-01-17 | Methods and compositions for blocking microbial adherence to eukaryotic cells |
Country Status (1)
Country | Link |
---|---|
US (1) | US7311925B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063694A1 (en) | 2013-10-31 | 2015-05-07 | Akthelia Pharmaceuticals | Antimicrobial compounds |
US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
WO2023242070A1 (en) | 2022-06-13 | 2023-12-21 | Akthelia Pharmaceuticals | Antimicrobial compounds |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050180962A1 (en) * | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
WO2005074911A1 (en) * | 2004-02-05 | 2005-08-18 | Ajinomoto Co., Inc. | Protein kinase c activator |
US20100216876A1 (en) * | 2007-10-02 | 2010-08-26 | Yuichi Suzuki | Antidiarrhetic composition, product containing the same and method of preventing diahhrea |
CL2009001506A1 (en) | 2009-07-01 | 2009-09-25 | Univ Concepcion | Quew |
RU2558792C2 (en) * | 2010-04-07 | 2015-08-10 | Оцука Фармасьютикал Фэктори, Инк. | Composition for improving general state accompanying hypoalbuminemia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6388056B1 (en) * | 1998-10-26 | 2002-05-14 | Paula Sundstrom | Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
US6607711B2 (en) * | 1997-10-07 | 2003-08-19 | Ejvind Jersie Pedersen | Mouth hygienic composition for the treatment of halitosis |
US6770306B1 (en) * | 1998-04-26 | 2004-08-03 | Zhongming Zeng | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
-
2002
- 2002-01-17 US US10/053,299 patent/US7311925B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607711B2 (en) * | 1997-10-07 | 2003-08-19 | Ejvind Jersie Pedersen | Mouth hygienic composition for the treatment of halitosis |
US6770306B1 (en) * | 1998-04-26 | 2004-08-03 | Zhongming Zeng | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof |
US6388056B1 (en) * | 1998-10-26 | 2002-05-14 | Paula Sundstrom | Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
Non-Patent Citations (20)
Title |
---|
Arvola T., Laiho K, Torkkeli S, Mykkanen H., Salminem S., Maumula L, and Isolauri E. Prophylactic Lactobacilius GG reduces antibiotic-associated diarrhea in children with respiratory infections:a randomized study. Pediatrics 104, e64, 1999. |
Boris S and Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect. 2, 543-546, 2000. |
Brighenti F, Casiraghi MC, Canzi E, and Ferrari A. Effect of consumption of a ready-to eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. European Journal of Clinical Nutrition 53, 726-733, 1999. |
Du Toit M, Franz CM, Dicks, LM, Schillinger U., Haberer P, Warlies B., Ahrens F, and Holzapfel W.H. Characterization and selection of probiotic lactobacilli for a preliminary minipig feeding trial and their effect on serum cholesterol levels, faeces pH and faeces moisture content. Int. J. Food Microbiol. 40, 93-104, 1998. |
Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D, Bazzocchi , Poggioli G., Miglioli M., and Campieri M. Oral bacteriotherapy as a maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 305-309, 2000. |
Guanalini S, Pensabebene L, Zikri MA, Dias JA, Casali LG, Hoekstra , Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, de Sousa JS, Sandhu B, Szajewska H, Weizman Z. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J. Pediatr. Gastroenterol. Nutr. 30. 54-60, 2000. |
Kelly CG and Younson JS. Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces. Expert Opin. Investig. Drugs 9, 1711-1721, 2000. |
Martin H.L., Richardson, B.A., Nyange, P.M., Lavreys, L., Hillier S.L., Chohan B., Mandaliya K., Ndinya-Achola J.O., Bwayo J. and Kreiss J. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexulally transmitted disease acquisition. J. Infect. Dis. 180,1863-1868, 1999. |
Merz AJ and So M. Interactions of pathogenic Neisseriae with epithelial cell membranes. Annu. Rev. Cell. Dev. Biol. 16, 423-457, 2000. |
Mohan B., Kadirvel A., Natarajan A. and Bhaskaran M. Effect of probiotic supplementation on growth, nitrogen utilization and serum cholesterol in broilers. British Poultry Science 37, 395-401, 1996. |
Mulvey MA, Schilling JD, Martinez JJ, Hultgren, SJ. From the cover: bad bugs and releagered bladders: interplay between uropathogenic Escherichia col and innate host defenses. Proc. Natl. Acad. Sci. USA 97, 8829-8835, 2000. |
Nobaek S., Johansson M-L., Molin G., Ahrne S., and Jeppsson B. Alteration of intestinal microflora is associated with a reduction in abdominal bloating and pain in patients with irritable bowel syndrome. American Journal of Gastroenterology 1231-1238, 2000. |
Petro T.M and Bhattacharjee J.K. Effect of dietary amino acid limitations upon native levels of murine immunoglobulins, transferrin, and complement. Infect. Immun. 27, 513-518, 1980. |
Petro T.M and Bhattacharjee J.K. Effect of dietary amino acid limitations upon the susceptibility to Salmonella typhimurium and the effect upon humoral and cellular immune responses in mice. Infect. Immun. 32, 251-259, 1981. |
Reid, G. Potential preventive strategies and therapies in urinary tract infection. World J. Urol. 17, 359-363, 1999. |
Sobel, J. Bacterial Vaginosis. Annu. Rev. Med. 51, 349-356, 2000. |
The Merck Index, An encyclopedia of Chemicals, Drugs, and Biologicals 883 (12<SUP>th </SUP>ed. 1996). * |
Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, and Young, RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. Journal of Pediatrics 135: 564-568, 1999. |
Venturî A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., Matteuzzi D., and Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1103-1108, 1999. |
Webster's New Collegiate Dictionary 41 (1976). * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
WO2015063694A1 (en) | 2013-10-31 | 2015-05-07 | Akthelia Pharmaceuticals | Antimicrobial compounds |
WO2023242070A1 (en) | 2022-06-13 | 2023-12-21 | Akthelia Pharmaceuticals | Antimicrobial compounds |
Also Published As
Publication number | Publication date |
---|---|
US20020131996A1 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alugongo et al. | Effects of Saccharomyces cerevisiae fermentation products on dairy calves: Performance and health | |
Videla et al. | New perspectives in equine gastric ulcer syndrome | |
DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
JP5497634B2 (en) | Probiotics in pre-operative and / or post-operative environments | |
CN1852708B (en) | Human beta-defensin secretion promoter | |
JP2002516072A (en) | Prevention of tartar by polycarboxylic acids | |
Zavoshti et al. | Therapeutics for equine gastric ulcer syndrome | |
JP2012512171A (en) | Compositions and methods for improved oral health | |
JPWO2005099725A1 (en) | Inflammatory bowel disease preventive and / or therapeutic agent | |
US5541165A (en) | Saliva substitute | |
US20190076497A1 (en) | Oral and intestinal health products | |
CN115210360A (en) | Novel lactobacillus reuteri LM1071 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising the same or culture thereof | |
US7311925B2 (en) | Methods and compositions for blocking microbial adherence to eukaryotic cells | |
KR102214820B1 (en) | Composition for improving of skin conditions | |
JP2014166972A (en) | Intestinal inflammation inhibitor and food and drink | |
US7470434B1 (en) | Methods and compositions for blocking microbial adherence to eukaryotic cells | |
US20100040711A1 (en) | Zinc-carnosine -based treatment for non ulcer (functional ) dyspepsia & irritable bowel syndrome in humans and other animals | |
JP2015120646A (en) | Wound therapeutic agent | |
KR100509249B1 (en) | Drugs, foods, drinks and feeds containing cocoa component | |
US20120213713A1 (en) | Compositions of omega fatty acids for the prevention and treatment of dental caries resulting from oral infections | |
Piva et al. | Possible alternatives to the use of antibiotics as growth promoters. New additives | |
EP3967318A1 (en) | Probiotic compositions for the treatment of acne | |
JP7281729B2 (en) | antifungal composition | |
US20240226196A9 (en) | Composition and Use Thereof | |
US20240131089A1 (en) | Composition and Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNATE IMMUNITY, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZASLOFF, MICHAEL A.;REEL/FRAME:016412/0728 Effective date: 20050310 |
|
AS | Assignment |
Owner name: ACTUA THERAPEUTICS, LLC, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANDERSON, GLENN M;REEL/FRAME:021998/0421 Effective date: 20081209 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
REMI | Maintenance fee reminder mailed | ||
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees | ||
REIN | Reinstatement after maintenance fee payment confirmed | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20151225 |
|
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20160621 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20191225 |